We compared the transcriptional level of ZDHHC5 in LUAD with that in normal samples using 3 independent studies from the Gene Expression Omnibus (GEO) database. In Figure 2A, the mRNA expression of ZDHHC5 was also significantly upregulated (fold change > 1, P < 0.05). The mass spectrometry results of ZDHHC5 from the CPTAC database (Figure 2B) revealed the over expression of ZDHHC5 protein in LUAD. There are 5 known immune subtypes within LUAD tumors (Thorsson et al., 2018), including C1 (wound healing), C2 (IFN-γ dominant), C3 (inflammatory), C4 (lymphocyte depleted), and C6 (TGF-β dominant); overall survival analysis stratified by immune subtype indicated that C3 had the most favorable prognosis, and C6 and C4 had the poorest outcome. This immunogenomics pipeline was used to characterize these heterogeneous tumors, and we used the resulting data to explore the distribution of ZDHHC5 in immune subtypes. ZDHHC5 was slightly downregulated in C3 and was overexpressed in C4 (Figure 2C), which is in accordance with the proposed malignant role of ZDHHC5 in LUAD. We also explored the Spearman correlation of ZDHHC5 with 3 types of
